OnKure Therapeutics (NASDAQ:OKUR) Stock Falls 4.8% – Here’s What Happened

Posted by Francis Steltz on Sep 29th, 2026

OnKure Therapeutics, Inc. (NASDAQ:OKUR – Get Free Report)’s share price dropped 4.8% during mid-day trading on Monday. The stock traded as low as $2.60 and last traded at $2.76. Approximately 442,229 shares changed hands during mid-day trading, an increase of 209% from the average daily volume of 142,954 shares. The stock had previously closed at $2.90.

Wall Street Analyst Weigh In

OKUR has been the topic of several research analyst reports. HC Wainwright lowered their target price on OnKure Therapeutics to $21.00 and set a “buy” rating on the stock in a research note on Monday, July 20th. Oppenheimer reissued an “outperform” rating and issued a $14.00 price target on shares of OnKure Therapeutics in a research report on Friday, August 14th. Wall Street Zen upgraded shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 21st. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $17.50.

Check Out Our Latest Stock Analysis on OKUR

OnKure Therapeutics Stock Down 4.8%

The stock’s 50 day moving average price is $3.67 and its two-hundred day moving average price is $4.04. The firm has a market capitalization of $111.50 million, a price-to-earnings ratio of -0.79 and a beta of 0.23.

OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.23. On average, equities analysts expect that OnKure Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Institutional Investors Weigh In On OnKure Therapeutics

Several large investors have recently made changes to their positions in the company. Vivo Capital LLC acquired a new position in OnKure Therapeutics in the first quarter worth approximately $7,981,000. Renaissance Technologies LLC raised its position in OnKure Therapeutics by 52.5% during the first quarter. Renaissance Technologies LLC now owns 377,250 shares of the company’s stock valued at $1,562,000 after acquiring an additional 129,900 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in OnKure Therapeutics in the second quarter valued at approximately $1,099,000. ADAR1 Capital Management LLC grew its position in OnKure Therapeutics by 140.1% in the first quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock worth $10,081,000 after acquiring an additional 1,420,783 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new stake in OnKure Therapeutics in the first quarter worth approximately $998,000. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

(Get Free Report)

OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company is working to discover and advance small-molecule therapies designed to target biological pathways involved in tumor growth and the suppression of antitumor immune responses.

Its lead investigational product candidate, OKN4395, is an orally administered small-molecule antagonist of the EP4 receptor, which is associated with tumor-promoting inflammation and immune suppression.